BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/5/2026 6:55:13 AM | Browse: 3 | Download: 10
 |
Received |
|
2025-07-16 02:34 |
|
Peer-Review Started |
|
2025-07-16 02:34 |
|
First Decision by Editorial Office Director |
|
2025-10-13 09:04 |
|
Return for Revision |
|
2025-10-13 14:01 |
|
Revised |
|
2025-10-13 16:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-15 02:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-16 01:58 |
|
Articles in Press |
|
2025-12-16 01:58 |
|
Edit the Manuscript by Language Editor |
|
2025-12-22 05:04 |
|
Typeset the Manuscript |
|
2025-12-30 05:47 |
|
Publish the Manuscript Online |
|
2026-01-05 06:55 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Discontinuation of advanced therapy in inflammatory bowel disease: Updated evidence, guidelines, and personalized decision-making one year later
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Salvatore Greco, Michele Campigotto and Nicolò Fabbri |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salvatore Greco, MD, Department of Internal Medicine, Ospedale del Delta, AUSL Ferrara, Via valle Oppio 2, Lagosanto 44023, Ferrara, Italy. grcsvt@unife.it |
| Key Words |
Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease; Biologic therapy; Discontinuation of therapy; Personalized medicine |
| Core Tip |
Discontinuation of advanced therapies in inflammatory bowel diseases remains a high-stakes decision, with relapse, immunogenicity, and long-term complications all weighing heavily. Despite updated international guidelines and emerging therapies, a personalized, closely monitored approach remains essential to ensure safe and effective treatment de-escalation in both Crohn’s disease and ulcerative colitis. |
| Publish Date |
2026-01-05 06:55 |
| Citation |
Greco S, Campigotto M, Fabbri N. Discontinuation of advanced therapy in inflammatory bowel disease: Updated evidence, guidelines, and personalized decision-making one year later. World J Clin Cases 2026; 14(1): 112021 |
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i1/112021.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i1.112021 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
